Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 17-Mar-2021 10:22:02. This version was issued on 17-Mar-2021 10:22:02

This alert has been issued to:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health

Action category: Action

Title: Convalescent Plasma in the Management of Hospitalised Patients with COVID-19

Broadcast content:
***Attachment re-posted on 23 March to remove the Draft watermark. No other change to the content.***

Results from the RECOVERY trial, a randomised, controlled, open-label, adaptive platform trial, showed no significant clinical benefit from treatment with high-titre convalescent plasma in patients hospitalised with COVID-19. 

The REMAP-CAP trial, an international randomised, embedded, multifactorial, adaptive platform trial has also announced that no significant benefit was seen from treatment with convalescent plasma (up to two ABO-compatible units administered over 48 hours) in patients requiring organ support in an intensive care setting.

It is therefore now recommended that convalescent plasma is NOT used in the management of hospitalised patients with confirmed or suspected SARS-CoV-2 infection.

Additional information: This alert is not relevant to Primary Care

Alert reference: CEM/CMO/2021/010


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency